Characteristics of COALL-92 study patients
. | All patients . | Low risk . | High risk . |
---|---|---|---|
No. of patients | 521 | 247 | 274 |
Sex | |||
Male | 306 | 142 | 164 |
Female | 215 | 105 | 110 |
Age, y | |||
Median | 4.8 | 4.1 | 6.5 |
Range | 1.0-17.8 | 1.0-9.9 | 1.0-17.8 |
Immunophenotype | |||
Pro-B-ALL | 13 | 0 | 13 |
Common ALL | 348 | 208 | 140 |
Pre-B-ALL | 82 | 39 | 43 |
T-ALL | 78 | 0 | 78 |
WBC × 109/L | |||
Median | 10.5 | 5.2 | 41.1 |
Range | 0.4-1258 | 0.4-24.5 | 0.4-1258 |
Primary CNS involvement | 16 | 1 | 15 |
Philadelphia chromosome positive | 7 | 0 | 7 |
. | All patients . | Low risk . | High risk . |
---|---|---|---|
No. of patients | 521 | 247 | 274 |
Sex | |||
Male | 306 | 142 | 164 |
Female | 215 | 105 | 110 |
Age, y | |||
Median | 4.8 | 4.1 | 6.5 |
Range | 1.0-17.8 | 1.0-9.9 | 1.0-17.8 |
Immunophenotype | |||
Pro-B-ALL | 13 | 0 | 13 |
Common ALL | 348 | 208 | 140 |
Pre-B-ALL | 82 | 39 | 43 |
T-ALL | 78 | 0 | 78 |
WBC × 109/L | |||
Median | 10.5 | 5.2 | 41.1 |
Range | 0.4-1258 | 0.4-24.5 | 0.4-1258 |
Primary CNS involvement | 16 | 1 | 15 |
Philadelphia chromosome positive | 7 | 0 | 7 |